Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) is a biopharmaceutical company developing prescription products in multiple therapeutic categories such as RA, psoriasis and other inflammatory conditions. These high-potential global opportunities are balanced by the development of the company’s orphan drug candidate Droxidopa, an oral therapeutic currently approved and marketed in Japan, for the treatment of neurogenic orthostatic hypotension.

Shares of the company surged 19% Thursday’s trading after the company announced additional analysis for a late-stage trial of its drug Droxidopa for the treatment of neurologic orthostatic hypotension. CHTP said Droxidopa’s study results showed significant improvements across five clinically relevant assessment criteria. The company said the data also supports the “exceptional safety and tolerability of Droxidopa.

The news follows the company’s announcement last week that preliminary results (the first of two pivotal phase III trials) for Droxidopa “did not demonstrate a statistically significant improvement relative to placebo.”

“We are encouraged by the breadth and depth of findings from Study 302 that demonstrate a symptomatic benefit and provide validation of the safety and tolerability of Droxidopa for the treatment of neurogenic orthostatic hypotension — a serious condition with an urgent need for improved treatments,” Dr. Simon Pedder, president and CEO of CHTP stated in the press release. “In looking ahead, we believe these results will be evident in the results of Study 301 expected this quarter. Further, we believe the outcome of Study 301 may be enhanced by the washout period included in that study. This belief is supported by open-label data from Study 301 that demonstrate a marked return of symptoms prior to randomization. The increase in average dizziness score from 1.0 following dose titration to 5.4 after a 7-day washout period in Study 301 suggests a reduction in the carry-over effect that appeared to follow sustained drug treatment prior to randomized withdrawal in Study 302.”

Moving Average Price Compare

ARNA is trading below its 50 day moving average. However, this moving average is trending higher which suggests that there has been buying interest in this stock.

MACD

The MACD for ARNA currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of 0, which implies that the underlying moving averages are trending lower.

Arena Pharmaceuticals Inc. (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company’s drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a phase III clinical trial program for the treatment of obesity. It has a pipeline of compounds that target G protein-coupled receptors (GPCRs), and includes compounds being evaluated independently and with its partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals Inc. On January 9, 2008, the Company acquired from Siegfried Ltd certain drug product facility assets, including a licensed production facility, fixtures, equipment, other personal property and real estate assets in Zofingen, Switzerland.

Source: http://finance.yahoo.com/q?s=ARNA, https://trading.scottrade.com/quotesresearch/ScottradeResearch.aspx?page=markets , http://www.reuters.com/finance/stocks/incomeStatement?stmtType=INC&perType=INT&symbol=ARNA.W

ARNA reported positive, highly significant top line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM confirms the results previously reported for the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial and completes the lorcaserin Phase 3 pivotal registration program of 7,190 patients evaluated for up to two years. Arena plans to submit a New Drug Application, or NDA, for lorcaserin to the US Food and Drug Administration, or FDA, in December. In the one year BLOSSOM trial, lorcaserin met all primary efficacy and safety endpoints. Patients achieved highly significant categorical and absolute weight loss. Lorcaserin was very well tolerated and was not associated with depression or suicidal ideation. The integrated echocardiographic data set from BLOSSOM and BLOOM rules out a risk of valvulopathy in lorcaserin patients according to criteria requested by the FDA. Treatment with lorcaserin also resulted in significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk.

63.2% of patients lost at least 5% of their body weight

35.1% of patients lost at least 10% of their body weight

Patients lost an average of 17.0 pounds, or 7.9% of their body weight; and

The quartile of lorcaserin patients with the greatest weight loss (among those with a Week 52 weight recorded) lost an average of 35.1 pounds, or 16.3% of their body weight.

Source: Scottrade.com, Reuters.com, http://biz.yahoo.com/e/090918/arna8-k.html

Moving Average Price Compare

ARNA is trading below its 13-day moving average, signaling a bullish sign as the moving average is trending lower.

MACD

The MACD for ARNA currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of 0, which implies that the underlying moving averages are trending lower.

Source: www.stockcharts.com

Apple Inc. (APPL), designs, manufactures and markets personal computers, portable digital music players, and mobile communication devices and sells a variety of related software, services, peripherals and networking solutions. The Company sells its products worldwide through its online stores, its retail stores, its direct sales force, and third-party wholesalers, resellers and value-added resellers. In addition, the Company sells a variety of third-party Macintosh (Mac), iPod and iPhone compatible products, including application software, printers, storage devices, speakers, headphones and various other accessories and peripherals through its online and retail stores, and digital content through the iTunes Store. It sells to consumer, small and mid-sized business (SMB), education, enterprise, government and creative customers.

The Company offers a range of personal computing products, including desktop and notebook computers, server and storage products, related devices and peripherals, and various third-party hardware products. The Company’s Mac desktop and portable systems feature Intel microprocessors, the Company’s Mac OS X Version 10.5 Leopard (Mac OS X Leopard) operating system and iLife suite of software for creation and management of digital photography, music, movies, digital versatile discs (DVD), and Website.

Source: https://trading.scottrade.com/quotesresearch/ScottradeResearch.aspx?symbol=AAPL, http://finance.yahoo.com/q?s=AAPL , http://www.reuters.com/finance/stocks/incomeStatement?stmtType=INC&perType=INT&symbol=AAPL.O

It was recently reported that AAPL was sued by a Colorado resident who accused it of misappropriating an “iconic” photo he possesses for the Company’s iPhone. In a lawsuit filed with the federal court in Manhattan, widely published photographer Louis Psihoyos contends that the Company is using his ’1000 TVs’ image in its ‘i.TV’ movie guide application for the iPhone. The plaintiff accused the Cupertino, California based company of copyright infringement of his image, which was created in 2005. He is seeking actual damages and other remedies that together are “reasonably believed” to exceed $2 million, according to the complaint.

AAPL was raised to buy from neutral by UBS, which said iPhone prospects look bright. It also said Apple may be working on building out a foundation for a service to provide seamless access and mobility of digital content across its products. UBS upped its Apple target to $265 from $170.

AAPL today announced that more than two billion apps have been downloaded from its revolutionary App Store, the largest applications store in the world. There are now more than 85,000 apps available to the more than 50 million iPhone(TM) and iPod touch® customers worldwide and over 125,000 developers in Apple’s iPhone Developer Program.

Many analysts project sales growth of 10% for FY 09 (Sep.) and 14% for FY 10, and believe the combination of AAPL’s opportunistic management, brand recognition, and innovative, integrative and quality products will result in share gains in the computer, handset and MP3 player and related markets. Some also see iPhone and iTunes sales largely offsetting slower desktop and iPod shipments. In addition many believe the release of a tablet/mobile Internet device would provide incremental sales opportunities.

Source: Scottrade.com, Reuters.com

Moving Average Price Compare

AAPL is trading above its 50-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

MACD

AAPL’s MACD is indicating a weak bearish signal. Although the indicator is above the critical level of 0, which implies that the underlying moving averages are bullish, the MACD has crossed below its 9-day moving average or signal line. This suggests that positive momentum has begun to slow.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.